Laboratorios Farmaceuticos Rovi, S.A. - Laporan Laba Rugi (TTM)

Laboratorios Farmaceuticos Rovi, S.A.
US ˙ OTCPK ˙ ES0157261019

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Laboratorios Farmaceuticos Rovi, S.A. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 413 420 450 519 581 649 724 739 761 818 814 818 837 830 779 778 799 764 767 749
Change (%) 1.77 7.04 15.42 12.03 11.59 11.57 2.12 2.93 7.50 -0.48 0.54 2.31 -0.90 -6.08 -0.14 2.73 -4.44 0.49 -2.41
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 183 183 198 240 253 269 289 287 304 305 300 315 314 346 336 316 310 296 295 282
Change (%) -0.05 8.04 21.36 5.53 6.27 7.49 -0.82 5.89 0.58 -1.73 4.86 -0.17 10.23 -2.92 -5.93 -1.84 -4.60 -0.34 -4.55
% of Revenue 44.32 43.53 43.94 46.20 43.52 41.44 39.93 38.78 39.90 37.33 36.86 38.45 37.51 41.73 43.14 40.63 38.83 38.76 38.44 37.60
Gross Operating Profit 230 237 252 279 328 380 435 452 457 512 514 504 523 483 443 462 489 468 472 467
Change (%) 3.21 6.27 10.77 17.62 15.68 14.45 4.07 1.05 12.09 0.26 -1.98 3.87 -7.59 -8.35 4.26 5.86 -4.34 1.01 -1.06
% of Revenue 55.68 56.47 56.06 53.80 56.48 58.56 60.07 61.22 60.10 62.67 63.14 61.55 62.49 58.27 56.86 59.37 61.17 61.24 61.56 62.40
SG&A 93 85 86 94 95 103 108 110 115 130 134 138 143 147 150 153 155 158 161 164
Change (%) -8.73 1.69 9.02 1.16 8.63 4.65 1.84 4.43 13.00 3.24 2.55 4.01 2.71 2.11 1.78 1.17 2.37 1.76 1.71
% of Revenue 22.52 20.20 19.19 18.12 16.37 15.93 14.95 14.90 15.12 15.90 16.49 16.82 17.10 17.72 19.27 19.64 19.34 20.72 20.98 21.87
R&D
Change (%)
% of Revenue
OpEx 350 345 358 415 436 469 503 519 546 564 568 583 585 610 601 587 587 585 585 576
Change (%) -1.32 3.62 16.08 5.06 7.45 7.40 3.17 5.11 3.35 0.64 2.68 0.46 4.20 -1.49 -2.27 -0.10 -0.28 -0.01 -1.48
% of Revenue 84.73 82.16 79.53 79.98 75.01 72.23 69.53 70.25 71.74 68.97 69.75 71.24 69.94 73.54 77.14 75.49 73.40 76.60 76.23 76.95
Operating Income 63 75 92 104 145 180 221 220 215 254 246 235 252 219 178 191 213 179 182 173
Change (%) 18.88 22.81 12.88 39.89 24.00 22.41 -0.29 -2.23 18.02 -2.98 -4.40 6.91 -12.77 -18.84 7.07 11.46 -15.93 2.10 -5.37
% of Revenue 15.27 17.84 20.47 20.02 24.99 27.77 30.47 29.75 28.26 31.03 30.25 28.76 30.06 26.46 22.86 24.51 26.60 23.40 23.77 23.05
Interest Expense -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -2 -3 -2 -3 -3
Change (%) 40.87 -45.15 15.14 6.50 25.52 -4.53 1.62 -0.46 -2.86 -6.60 -0.88 3.69 16.32 24.16 60.15 61.75 -22.93 13.32 13.93
% of Revenue -0.18 -0.26 -0.13 -0.13 -0.12 -0.14 -0.12 -0.12 -0.11 -0.10 -0.10 -0.10 -0.10 -0.11 -0.15 -0.24 -0.38 -0.31 -0.35 -0.41
Net Income 55 61 71 82 113 153 182 183 176 200 194 186 197 170 138 148 165 137 140 132
Change (%) 10.18 16.25 16.22 37.20 35.26 19.08 0.21 -3.85 13.68 -2.80 -4.32 6.08 -13.53 -19.08 7.40 11.46 -17.04 2.29 -5.53
% of Revenue 13.43 14.54 15.79 15.90 19.47 23.60 25.19 24.72 23.09 24.42 23.85 22.70 23.53 20.53 17.69 19.03 20.64 17.92 18.24 17.66

Source: Capital IQ

Other Listings
IT:1ROVI € 59.50
ES:ROVI € 59.65
GB:ROVIE
DE:41L € 60.00
AT:ROVI
GB:0ILL
MX:ROVI N
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista